- Design
- Systematic review and random-effects meta-analysis of 3 RCTs
- Population
- 14,239 patients with acute non-cardioembolic ischaemic stroke or TIA
- Primary outcome
- Any stroke; major bleeding
- Effect
- Any stroke RR 0.75 (95% CI 0.66–0.84); major bleeding RR 1.12 (0.87–1.44)
This systematic review pooled three randomised placebo-controlled trials of factor XIa inhibitors added to standard antiplatelet therapy after acute non-cardioembolic ischaemic stroke or TIA — 14,239 patients in total, with one phase 3 trial of 12,327 contributing most of the weight.
Factor XIa inhibitors reduced any stroke (RR 0.75, 95% CI 0.66–0.84), ischaemic stroke (RR 0.74, 0.66–0.84) and composite cardiovascular events (RR 0.83, 0.75–0.92). Major bleeding (RR 1.12, 0.87–1.44), haemorrhagic stroke, intracranial haemorrhage, any bleeding and all-cause mortality did not rise significantly.
If the phase 3 result holds and regulators act on it, this would be the first anticoagulant strategy to show benefit on top of antiplatelets in non-cardioembolic stroke — a group where adding warfarin or a DOAC has consistently failed because of bleeding. The regulatory status of these agents for this indication, including in India, is not established in this paper.
- Factor XIa inhibitors are not yet standard care; do not add off-label anticoagulants to antiplatelets outside trials.
- Expect about one in four recurrent strokes to be prevented if these agents reach practice.
- No significant rise in major bleeding or intracranial haemorrhage was seen, unlike older anticoagulants in this setting.
- Keep optimising current secondary prevention: antiplatelet therapy, blood pressure, statin, diabetes and smoking.
- Watch for regulatory decisions on factor XIa inhibitors for secondary stroke prevention.
Why it matters
It suggests uncoupling thrombosis from haemostasis may finally let anticoagulation help in non-cardioembolic stroke.
Don't overread it
The pooled estimate rests largely on one phase 3 trial, and no regulator's decision is reported here.
The statistics, in plain English
A risk ratio of 0.75 means about 25% fewer strokes. The bleeding risk ratio of 1.12 has an interval from 0.87 to 1.44, which crosses 1.0 — no significant increase, but a modest rise cannot be ruled out. Because one large trial supplies most of the data, this meta-analysis mostly restates that trial rather than confirming it independently.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for neurology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free